(CDAX, Technology, BSL GR)



Buy EUR 28.00	(EUR 33.00)	Value Indicators: DCF: FCF-Value Potential 25e:	28.01	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	2.7 3.0 4.0 1.0	Description: B2B digital cameras for appli such as factory, medical, traf retail.	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	271.9	Freefloat	38.00 %	Beta:	1.2
Price	EUR 8.95	No. of shares (m):	30.4	Norbert Basler	53.00 %	Price / Book:	2.2 x
Upside	212.8 %	EV:	333.0	Treasury shares	5.00 %	Equity Ratio:	48 %
		Freefloat MC:	103.3	Dr. Ley (CEO)	4.00 %	Net Fin. Debt / EBITDA:	9.6 x
		Ø Trad. Vol. (30d):	330.89 th	Invesco	6.00 %	Net Debt / EBITDA:	9.9 x

Guidance adjusted to lower end of target as market softness continues

Stated Figur	es Q3/2	2023:							Comment on Figures:
FY End: 31.12. in EUR m	Q3 23	Q3 23e	Q3 22	уоу	9M 23	9M 23e	9M 22	уоу	 Decline in sales due to inflated customer inventory and continued market softness, especially in Asia and North America
Sales EBT <i>Margin</i> EPS	41.5 -16.3 -39.3 % -0.52	46.2 -16.9 -36.6 % -0.53	74.4 9.5 12.8 % 0.26	-44 % n.a. n.a.	157.5 -16.1 -10.2 % -0.58	162.3 -16.7 -10.3 % -0.59	205.2 24.3 11.8 % 0.64	-23 % n.a. n.a.	 Low capacity utilization and high-priced material bought during the shortages burdened gross profits EBIT includes restructuring one-offs of EUR 10.3m

Basler published Q3 figures und adjusted the full-year guidance towards the lower end of the target. Sales of EUR 41.5m were below our estimate of EUR 46.2m, but EBT was better than expected at EUR -16.1m (WRe EUR -16.7m). The demand-lull continued, driven by inflated inventories at Basler's customers, built up during the shortages, and overcapacity in consumer electronics, logistics and lab automation after increased demand during the pandemic. This was also reflected in order intake, which declined compared to last year from EUR 50.4m to EUR 34.3m and even fell below the Q2 level (EUR 39.9m).

Although visibility of a recovery in underlying market demand remains low, some temporary impediments are easing. Order cancellations declined significantly to only EUR 0.9m after EUR 23.1m in H1. Lead times have also normalized from several months during the shortages to weeks. Approx. 70% of current order backlog of EUR 40.5m is scheduled for delivery in Q4, providing solid visibility for the FY targets. The inventory at Basler's customers should have mostly returned to normal levels by the end of the year.

EBT was burdened by low capacity utilization and high-priced material bought during the shortages. In addition, one-off costs of EUR 10.3m from the restructuring programme (EUR 5.7m personnel reduction, EUR 3.9m write-offs on capitalized R&D and EUR 0.7m write-downs on inventories) were included in the figure. As scheduled, the bulk of the measures were implemented in Q3 and should show first positive cost effects in Q4.


We have adjusted our estimates to better reflect the limited visibility of a short-term recovery in underlying market demand. However, with the restructuring measures and the planned headcount reduction of 200 FTEs, we expect Basler to return to its mid-term EBT-margin target of 12% by 2025 despite the lower sales volume. Based on our estimates, Basler is currently priced at a PE 2025e of 11.0x, which appears attractive considering the company's strong track record and market position. We have reduced our target but confirm our Buy recommendation.

Changes in E	Estimates:						Comment on Changes:
FY End: 31.12. in EUR m	2023e (old)	+ / -	2024e (old)	+ / -	2025e (old)	+ / -	 Reduction in growth forecast to reflect the limited visibility of a recovery in underlying market demand
Sales	214.3	-5.6 %	242.5	-7.3 %	316.4	-9.0 %	 Lower margin expected in 2024 - underutilization of production capacity In 2025, color, growth and the cost reduction from the restructuring
EBT	-18.2 -0.64	n.m. n m	12.1 0.29	-12.1 % -13 8 %			programme should result in higher profitability
					37.2 0.88	-9.0 % -6.9 % -6.8 %	 In 2025, sales growth and the cost reduction from the restructuring programme should result in higher profitability

40 -	FY End: 31.12.	CAGR							
35 - A Aman manager and	in EUR m	(22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
30 Will Juliu and	Sales	1.9 %	162.0	170.5	214.7	272.2	202.3	224.7	287.8
30 -	Change Sales yoy		8.0 %	5.2 %	26.0 %	26.8 %	-25.7 %	11.1 %	28.1 %
25 -	Gross profit margin		50.9 %	52.0 %	52.4 %	48.9 %	44.3 %	48.8 %	51.6 %
23	EBITDA	10.5 %	30.0	34.6	44.5	45.8	6.2	35.7	61.7
20 -	Margin		18.5 %	20.3 %	20.7 %	16.8 %	3.0 %	15.9 %	21.4 %
15 -	EBIT	8.0 %	17.0	20.1	28.4	28.9	-17.4	12.4	36.4
	Margin		10.5 %	11.8 %	13.2 %	10.6 %	-8.6 %	5.5 %	12.6 %
10 -	EBT		16.9	20.4	28.0	28.3	-19.0	10.7	34.6
	Margin		10.4 %	12.0 %	13.0 %	10.4 %	-9.4 %	4.7 %	12.0 %
01/23 03/23 05/23 07/23 09/	²³ ^{11/23} Net income	5.3 %	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
Basler — CDAX (normalised)	EPS	4.9 %	0.43	0.50	0.69	0.71	-0.67	0.25	0.82
Rel. Performance vs CDAX:	DPS	17.9 %	0.09	0.19	0.21	0.14	0.00	0.06	0.23
	Dividend Yield		0.6 %	1.1 %	0.5 %	0.4 %	n.a.	0.7 %	2.6 %
1 month:	-0.2 % FCFPS		-0.32	0.46	0.32	-0.59	-0.27	0.79	0.74
6 months:	-51.8 % FCF / Market cap		-2.1 %	2.6 %	0.8 %	-1.8 %	-3.0 %	8.8 %	8.2 %
Year to date:	-74.8 % EV / Sales		3.0 x	3.2 x	5.5 x	3.7 x	1.6 x	1.4 x	1.0 x
Trailing 12 months:	-78.1 % EV / EBITDA		16.1 x	15.6 x	26.5 x	22.3 x	54.0 x	8.7 x	4.8 x
5	EV / EBIT		28.4 x	26.9 x	41.7 x	35.2 x	n.a.	25.2 x	8.1 x
Company events:	P/E		36.4 x	36.1 x	57.2 x	45.6 x	n.a.	35.8 x	10.9 x
	FCF Potential Yiel	d	4.3 %	4.6 %	2.5 %	3.1 %	-0.3 %	8.3 %	14.7 %
	ROE		14.4 %	13.9 %	17.0 %	15.8 %	-15.2 %	6.0 %	18.1 %
	ROCE (NOPAT)		12.7 %	12.8 %	17.3 %	13.5 %	n.a.	5.0 %	15.5 %
	Guidance:	Sales EUR 20	0-205m, EB	TEUR -18m	to -20m				

Analyst **Robert-Jan van der Horst** rvanderhorst@warburg-research.com +49 40 309537-290






Company Background

- Basler is a full-line supplier of camera solutions for production, medical applications, traffic control or retail.
- Basler focuses on the mainstream and entry-level market segments.
- Customers are mainly OEMs. The customer base is well diversified and no single customer accounts for more than 10% of revenue. Almost 80% of revenues are direct sales.

Competitive Quality

- In terms of units Basler is the world's largest developer and manufacturer of digital cameras in a fragmented, but consolidating, market for digital cameras for B2B-applications.
- High level of vision technology expertise: Basler has one of the largest developer pools in the sector and differentiates itself with camera software competence, which accounts for more than 50% of the value creation.
- State-of-the-art product portfolio: Basler is among the first movers in digital cameras based on GigE Vision and the USB3 Vision standard. It is also an early adopter of new sensor technology.
- High service and consulting quality through direct sales and Basler's network of specialised distributors.
- Basler is present in the most important markets for vision technology in South East Asia, Europe and the US.





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	
Sales	202.3	224.7	287.8	334.7	387.9	448.0	515.7	591.7	676.6	771.4	876.7	993.4	1,125.6	
Sales change	-25.7 %	11.1 %	28.1 %	16.3 %	15.9 %	15.5 %	15.1 %	14.7 %	14.4 %	14.0 %	13.7 %	13.3 %	13.3 %	2.5 %
EBIT	-17.4	12.4	36.4	42.2	48.5	56.0	64.5	74.0	84.6	96.4	112.2	124.2	140.7	
EBIT-margin	-8.6 %	5.5 %	12.6 %	12.6 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.5 %	12.8 %	12.5 %	12.5 %	
Tax rate (EBT)	-6.3 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
NOPAT	-18.5	8.9	26.2	30.4	34.9	40.3	46.4	53.2	60.9	69.4	80.8	89.4	101.3	
Depreciation	23.6	23.3	25.3	22.8	25.2	29.1	33.5	38.5	44.0	50.1	57.0	64.6	73.2	
in % of Sales	11.7 %	10.4 %	8.8 %	6.8 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Changes in provisions	0.0	0.0	0.0	0.3	0.4	0.4	0.5	0.5	0.6	0.6	0.7	0.8	0.9	
Change in Liquidity from														
- Working Capital	-10.5	-13.1	1.5	7.6	8.4	10.2	11.5	12.9	14.4	16.1	17.9	19.8	22.5	
- Capex	16.1	20.5	26.9	23.4	26.8	30.5	34.0	38.5	44.0	50.1	57.0	64.6	73.2	
Capex in % of Sales	8.0 %	9.1 %	9.3 %	7.0 %	6.9 %	6.8 %	6.6 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
- Other	-17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	17.0	24.7	23.1	22.4	25.3	29.2	34.9	40.9	47.0	54.0	63.6	70.4	79.7	99
PV of FCF	17.1	22.8	19.7	17.6	18.3	19.4	21.3	23.0	24.4	25.8	28.0	28.5	29.8	611
share of PVs		6.57 %						26.04	4 %					67.39 %
Model parameter							Valuat	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20	035e	29	96			
								al Value		61				
Debt ratio	8.00 %		Financial S	•		1.20		al liabilitie		7	79			
Cost of debt (after tax)	2.1 %		Liquidity (s	hare)		1.20		n liabilities	;		2			
Market return	8.25 %		Cyclicality			1.30	Hybrid	•			0			
Risk free rate	2.75 %		Transpare	ncy		1.00		y interest			0			
			Others			1.10		val. of inv	estments		0			
							Liquidit	5				No. of sha	()	30.4
WACC	8.57 %		Beta			1.16	Equity	Value		85	51	Value per	share (E	UR) 28.01

Sensitivity Value per Share (EUR)

		Terminal	Growth								Delta EBIT	-margin					
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1 .0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.36	9.6 %	21.32	21.78	22.28	22.81	23.37	23.98	24.64	1.36	9.6 %	19.47	20.58	21.69	22.81	23.92	25.03	26.14
1.26	9.1 %	23.40	23.95	24.55	25.20	25.89	26.65	27.46	1.26	9.1 %	21.55	22.77	23.98	25.20	26.41	27.63	28.84
1.21	8.8 %	24.55	25.17	25.83	26.55	27.32	28.16	29.08	1.21	8.8 %	22.73	24.00	25.27	26.55	27.82	29.09	30.36
1.16	8.6 %	25.80	26.48	27.22	28.01	28.88	29.82	30.85	1.16	8.6 %	24.01	25.34	26.68	28.01	29.35	30.68	32.02
1.11	8.3 %	27.15	27.91	28.72	29.61	30.58	31.64	32.80	1.11	8.3 %	25.40	26.81	28.21	29.61	31.02	32.42	33.82
1.06	8.1 %	28.62	29.46	30.37	31.37	32.45	33.65	34.97	1.06	8.1 %	26.93	28.41	29.89	31.37	32.84	34.32	35.80
0.96	7.6 %	31.95	33.01	34.16	35.42	36.82	38.37	40.09	0.96	7.6 %	30.47	32.12	33.77	35.42	37.07	38.72	40.37

• Financial liabilities are also related to the lease of the company building.

• The beta takes into consideration Basler's strong track record, the high equity ratio and the cyclicality

• The structural growth of the vision technology market forms the basis of Basler's revenue increases.

- Cash inflow from treasury share sales are accounted for in the "others" line



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net Income before minorities	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
+ Depreciation + Amortisation	12.9	14.5	16.2	16.8	23.6	23.3	25.3
- Net Interest Income	-0.1	0.4	-0.4	-0.6	-1.6	-1.7	-1.8
- Maintenance Capex	5.0	4.4	7.5	7.5	6.1	6.7	8.6
+ Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Free Cash Flow Potential	20.9	24.9	29.8	31.3	-1.1	25.9	43.4
FCF Potential Yield (on market EV)	4.3 %	4.6 %	2.5 %	3.1 %	-0.3 %	8.3 %	14.7 %
WACC	8.57 %	8.57 %	8.57 %	8.57 %	8.57 %	8.57 %	8.57 %
= Enterprise Value (EV)	482.9	540.1	1,181.7	1,019.3	333.0	311.9	294.3
= Fair Enterprise Value	244.2	290.7	347.9	365.0	n.a.	302.6	506.3
- Net Debt (Cash)	50.4	50.4	50.4	50.4	59.2	38.1	20.5
- Pension Liabilities	2.0	2.0	2.0	2.0	2.0	2.0	2.0
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
 Market value of minorities 	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	191.8	238.3	295.6	312.6	n.a.	262.6	483.9
Number of shares, average	29.8	30.0	29.9	29.9	30.1	30.4	30.4
= Fair value per share (EUR)	6.43	7.94	9.88	10.46	n.a.	8.64	15.93
premium (-) / discount (+) in %						-3.4 %	78.0 %
Sensitivity Fair value per Share (EUR)						
11.57	7 % 4.23	5.36	6.76	7.18	n.a.	6.06	11.61
10.57	7 % 4.79	6.03	7.56	8.02	n.a.	6.76	12.78
9.57		6.84	8.53	9.04	n.a.	7.60	14.19
WACC 8.57		7.94	9.88	10.46	n.a.	8.64	15.93
7.57		9.11	11.24	11.88	n.a.	9.96	18.13
6.57		10.76	13.22	13.95	n.a.	11.68	21.01
5.57	7 % 10.64	13.00	15.90	16.77	n.a.	14.01	24.91

Assumptions on the beta and the wacc are consistent with indicators used in our DCF model

• The capex requirements for machinery and plant are low.



Valuation							
	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	4.5 x	4.7 x	9.2 x	6.8 x	2.2 x	2.1 x	1.8 x
Book value per share ex intangibles	1.32	1.62	2.09	1.57	1.03	1.12	1.60
EV / Sales	3.0 x	3.2 x	5.5 x	3.7 x	1.6 x	1.4 x	1.0 x
EV / EBITDA	16.1 x	15.6 x	26.5 x	22.3 x	54.0 x	8.7 x	4.8 x
EV / EBIT	28.4 x	26.9 x	41.7 x	35.2 x	n.a.	25.2 x	8.1 x
EV / EBIT adj.*	28.4 x	26.9 x	41.7 x	35.2 x	n.a.	25.2 x	8.1 x
P / FCF	n.a.	39.2 x	122.9 x	n.a.	n.a.	11.3 x	12.2 x
P/E	36.4 x	36.1 x	57.2 x	45.6 x	n.a.	35.8 x	10.9 x
P / E adj.*	36.4 x	36.8 x	57.2 x	45.6 x	n.a.	35.8 x	10.9 x
Dividend Yield	0.6 %	1.1 %	0.5 %	0.4 %	n.a.	0.7 %	2.6 %
FCF Potential Yield (on market EV)	4.3 %	4.6 %	2.5 %	3.1 %	-0.3 %	8.3 %	14.7 %
*Adjustments made for: -							




Consolidated profit and loss

In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	162.0	170.5	214.7	272.2	202.3	224.7	287.8
Change Sales yoy	8.0 %	5.2 %	26.0 %	26.8 %	-25.7 %	11.1 %	28.1 %
COGS	79.5	81.7	102.2	139.0	112.7	115.0	139.3
Gross profit	82.4	88.7	112.5	133.2	89.6	109.7	148.5
Gross margin	50.9 %	52.0 %	52.4 %	48.9 %	44.3 %	48.8 %	51.6 %
Research and development	17.9	21.7	29.9	31.4	40.9	36.2	40.4
Sales and marketing	31.5	30.6	34.9	47.9	40.3	37.1	43.7
Administration expenses	15.8	17.4	20.4	26.7	27.5	24.9	28.5
Other operating expenses	1.0	0.2	0.3	0.5	0.3	0.5	0.7
Other operating income	0.8	1.1	1.3	2.3	1.9	1.4	1.2
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	30.0	34.6	44.5	45.8	6.2	35.7	61.7
Margin	18.5 %	20.3 %	20.7 %	16.8 %	3.0 %	15.9 %	21.4 %
Depreciation of fixed assets	5.0	6.3	6.3	5.5	8.5	7.2	7.8
EBITA	25.0	28.3	38.2	40.2	-2.3	28.5	53.9
Amortisation of intangible assets	8.0	8.2	9.8	11.3	15.1	16.1	17.5
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	17.0	20.1	28.4	28.9	-17.4	12.4	36.4
Margin	10.5 %	11.8 %	13.2 %	10.6 %	-8.6 %	5.5 %	12.6 %
EBIT adj.	17.0	20.1	28.4	28.9	-17.4	12.4	36.4
Interest income	1.0	1.1	0.2	0.3	0.2	0.2	0.2
Interest expenses	1.1	0.8	0.6	1.0	1.8	1.9	2.0
Other financial income (loss)	0.0	0.0	0.0	0.2	0.0	0.0	0.0
EBT	16.9	20.4	28.0	28.3	-19.0	10.7	34.6
Margin	10.4 %	12.0 %	13.0 %	10.4 %	-9.4 %	4.7 %	12.0 %
Total taxes	4.0	5.3	7.2	7.0	1.2	3.0	9.7
Net income from continuing operations	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
Margin	7.9 %	8.9 %	9.7 %	7.8 %	-10.0 %	3.4 %	8.7 %
Number of shares, average	29.8	30.0	29.9	29.9	30.1	30.4	30.4
EPS	0.43	0.50	0.69	0.71	-0.67	0.25	0.82
EPS adj.	0.43	0.49	0.69	0.71	-0.67	0.25	0.82
*Adjustments made for:							


Guidance: Sales EUR 200-205m, EBT EUR -18m to -20m

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	40.4 %	40.3 %	39.2 %	38.3 %	52.9 %	43.3 %	39.0 %
Operating Leverage	-3.9 x	3.4 x	1.6 x	0.1 x	n.a.	n.a.	6.9 x
EBITDA / Interest expenses	28.3 x	45.0 x	75.4 x	43.8 x	3.4 x	18.8 x	30.9 x
Tax rate (EBT)	23.9 %	26.0 %	25.8 %	24.6 %	-6.3 %	28.0 %	28.0 %
Dividend Payout Ratio	20.1 %	38.4 %	29.8 %	19.6 %	0.0 %	23.8 %	28.0 %
Sales per Employee	200,944	210,964	248,528	240,462	217,060	200,267	248,532



Performance per Share




Consolidated balance sheet




In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	62.0	64.8	66.0	94.5	93.9	94.3	98.5
thereof other intangible assets	3.0	3.7	6.5	13.8	13.5	14.9	17.0
thereof Goodwill	27.5	27.5	27.5	46.1	46.1	46.1	46.1
Property, plant and equipment	30.6	29.3	28.7	29.4	32.9	27.8	23.1
Financial assets	4.6	2.2	0.0	1.4	1.4	1.4	1.4
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	97.2	96.3	94.7	125.3	128.3	123.5	123.1
Inventories	20.9	20.0	37.1	50.3	45.0	36.2	37.4
Accounts receivable	19.4	19.5	33.3	41.2	31.0	27.7	31.5
Liquid assets	35.2	47.9	54.8	28.7	36.7	57.9	75.5
Other short-term assets	8.5	6.5	7.3	20.0	20.0	20.0	20.0
Current assets	84.0	93.8	132.5	140.2	132.7	141.7	164.4
Total Assets	181.2	190.1	227.3	265.5	261.0	265.3	287.5
Liabilities and shareholders' equity							
Subscribed capital	10.0	10.0	10.0	29.8	30.7	30.7	30.7
Capital reserve	22.4	22.6	26.8	7.2	10.7	10.7	10.7
Retained earnings	74.8	87.1	94.2	107.2	87.0	94.6	119.5
Other equity components	-4.2	-4.8	-2.4	-2.8	-3.2	-7.6	-13.8
Shareholders' equity	103.0	114.9	128.7	141.5	125.2	128.4	147.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	103.0	114.9	128.7	141.5	125.2	128.4	147.1
Provisions	8.2	9.4	16.0	14.6	14.6	14.6	14.6
thereof provisions for pensions and similar obligations	0.9	1.1	1.6	2.0	2.0	2.0	2.0
Financial liabilities (total)	50.0	45.1	54.4	79.1	95.9	95.9	95.9
Short-term financial liabilities	5.3	4.1	4.1	4.0	6.0	6.0	6.0
Accounts payable	10.6	11.1	18.8	19.4	14.4	15.4	18.9
Other liabilities	9.4	9.7	9.4	10.9	10.9	10.9	10.9
Liabilities	78.2	75.2	98.6	124.0	135.9	136.9	140.4
Total liabilities and shareholders' equity	181.2	190.1	227.3	265.5	261.0	265.3	287.5

Financial Ratios

	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	2.7 x	3.0 x	2.7 x	2.7 x	2.1 x	2.9 x	3.9 x
Capital Employed Turnover	1.4 x	1.5 x	1.7 x	1.4 x	1.1 x	1.3 x	1.7 x
ROA	13.2 %	15.7 %	21.9 %	17.0 %	-15.8 %	6.2 %	20.2 %
Return on Capital							
ROCE (NOPAT)	12.7 %	12.8 %	17.3 %	13.5 %	n.a.	5.0 %	15.5 %
ROE	14.4 %	13.9 %	17.0 %	15.8 %	-15.2 %	6.0 %	18.1 %
Adj. ROE	14.4 %	13.4 %	17.0 %	15.8 %	-15.2 %	6.0 %	18.1 %
Balance sheet quality							
Net Debt	15.7	-1.7	1.2	52.4	61.2	40.0	22.4
Net Financial Debt	14.9	-2.8	-0.4	50.4	59.2	38.1	20.5
Net Gearing	15.3 %	-1.5 %	0.9 %	37.0 %	48.9 %	31.2 %	15.2 %
Net Fin. Debt / EBITDA	49.6 %	n.a.	n.a.	110.2 %	959.7 %	106.8 %	33.2 %
Book Value / Share	3.3	3.7	4.3	4.7	4.1	4.2	4.8
Book value per share ex intangibles	1.3	1.6	2.1	1.6	1.0	1.1	1.6



Book Value per Share in EUR



COMMENT

Published 09.11.2023

Consolidated cash flow statement




In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	12.9	15.1	20.8	21.4	-20.2	7.7	24.9
Depreciation of fixed assets	5.0	6.3	6.3	5.5	8.5	7.2	7.8
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	8.0	8.2	9.8	11.3	15.1	16.1	17.5
Increase/decrease in long-term provisions	-0.1	1.1	6.6	-1.3	0.0	0.0	0.0
Other non-cash income and expenses	-3.7	5.1	5.1	0.0	-2.0	0.5	0.5
Cash Flow before NWC change	22.1	35.9	48.6	36.9	1.4	31.5	50.7
Increase / decrease in inventory	0.1	0.9	-17.1	-13.2	5.3	8.8	-1.2
Increase / decrease in accounts receivable	-1.1	-0.1	-13.8	-7.9	10.2	3.3	-3.8
Increase / decrease in accounts payable	3.2	0.5	7.8	0.6	-5.0	1.0	3.5
Increase / decrease in other working capital positions	0.5	0.1	-0.1	-4.0	-4.0	0.0	0.0
Increase / decrease in working capital (total)	2.7	1.5	-23.2	-24.5	6.5	13.1	-1.5
Net cash provided by operating activities [1]	24.7	37.3	25.3	12.4	7.9	44.6	49.2
Investments in intangible assets	-29.3	-20.6	-11.8	-20.8	-14.5	-16.5	-21.7
Investments in property, plant and equipment	-5.1	-2.7	-3.9	-8.6	-1.6	-4.0	-5.2
Payments for acquisitions	0.0	0.0	0.0	-14.5	-1.0	-1.0	-1.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.1	0.2	0.4	0.3	0.1	0.1	0.1
Net cash provided by investing activities [2]	-34.2	-23.3	-15.3	-44.2	-17.0	-21.4	-27.8
Change in financial liabilities	-1.8	2.3	10.4	18.0	6.8	0.0	0.0
Dividends paid	-5.1	-2.6	-5.8	-6.2	-4.2	0.0	-1.8
Purchase of own shares	20.8	-0.2	-3.9	-2.7	17.6	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-1.0	-0.8	0.1	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	13.0	-1.3	-3.1	5.7	17.2	-2.0	-3.8
Change in liquid funds [1]+[2]+[3]	3.5	12.7	7.0	-26.1	8.0	21.1	17.6
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	35.3	47.9	54.8	28.7	36.7	57.9	75.5

Financial Ratios

	_ · · · ·						
	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	-9.6	13.8	9.6	-17.6	-8.2	24.0	22.3
Free Cash Flow / Sales	-5.9 %	8.1 %	4.5 %	-6.5 %	-4.1 %	10.7 %	7.8 %
Free Cash Flow Potential	20.9	24.9	29.8	31.3	-1.1	25.9	43.4
Free Cash Flow / Net Profit	-74.6 %	91.6 %	46.3 %	-82.3 %	40.8 %	313.2 %	89.6 %
Interest Received / Avg. Cash	2.9 %	2.7 %	0.4 %	0.7 %	0.6 %	0.4 %	0.3 %
Interest Paid / Avg. Debt	2.4 %	1.6 %	1.2 %	1.6 %	2.1 %	2.0 %	2.1 %
Management of Funds							
Investment ratio	21.2 %	13.7 %	7.3 %	10.8 %	8.0 %	9.1 %	9.3 %
Maint. Capex / Sales	3.1 %	2.6 %	3.5 %	2.8 %	3.0 %	3.0 %	3.0 %
Capex / Dep	265.4 %	160.6 %	97.2 %	174.8 %	68.3 %	88.2 %	106.2 %
Avg. Working Capital / Sales	19.0 %	17.1 %	18.6 %	22.7 %	33.0 %	24.5 %	17.1 %
Trade Debtors / Trade Creditors	183.1 %	175.9 %	176.9 %	212.1 %	215.3 %	179.9 %	166.7 %
Inventory Turnover	3.8 x	4.1 x	2.8 x	2.8 x	2.5 x	3.2 x	3.7 x
Receivables collection period (days)	44	42	57	55	56	45	40
Payables payment period (days)	49	49	67	51	47	49	50
Cash conversion cycle (Days)	91	82	122	136	155	111	88

CAPEX and Cash Flow




Free Cash Flow Generation

2021

FCF (m) - Free Cash Flow / Sales

Working Capital



COMMENT

Published 09.11.2023

2022 2023e 2024e 2025e

8



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 month	
Basler	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005102008.htm	



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	156	73
Hold	45	21
Sell	6	3
Rating suspended	6	3
Total	213	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	44	83
Hold	7	13
Sell	0	0
Rating suspended	2	4
Total	53	100

PRICE AND RATING HISTORY BASLER AS OF 09.11.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech, Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg Financial Services Fabio Hölscher Automobiles, Car Suppliers Philipp Kaiser Real Estate, Construction

Thilo Kleibauer Retail Consumer Goods

Head of Equity Sales, Germany

Marc Niemann

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

Matthias Fritsch

Maximilian Martin

SALES TRADING

United Kingdom

Austria, Poland

Oliver Merckel

Rico Müller

Sales Trading **Bastian Quast**

Sales Trading

Carsten Klude

Macro Research

Head of Sales Trading

United Kingdom, Ireland

United Kinadom

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-240 fhoelscher@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com +49 40 309537-257 tkleibauer@warburg-research.com

Hannes Müller Software, I Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate, Telco Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

+49 40 309537-255 hmueller@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140

Rudolf Alexander Michaelis Germany **Roman Alexander Niklas** Switzerland

Antonia Möller Roadshow/Marketing **Charlotte Wernicke** Roadshow/Marketing Juliane Niemann

Roadshow/Marketing

DESIGNATED SPONSORING

Marcel Magiera Designated Sponsoring Sebastian Schulz Designated Sponsoring Jörg Treptow Designated Sponsoring

Dr. Christian Jasperneite Investment Strategy

+49 40 3282-2649 rmichaelis@mmwarburg.com +49 69 5050-7412 rniklas@mmwarburg.com

awolf@warburg-research.com

+49 69 5050-7417 amoeller@mmwarburg.com +49 40 3282-2669 cwernicke@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2662 mmagiera@mmwarburg.com +49 40 3282-2631 sschulz@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

cjasperneite@mmwarburg.com

+49 40 3282-2439

MACRO RESEARCH

+49 40 3282-2572 cklude@mmwarburg.com

Our research can be found under:

Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please con	tact:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com



+49 40 3282-2678 mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com

+49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com +49 69 5050-7413 mmartin@mmwarburg.com

+49 40 3282-2634 omerckel@mmwarburg.com +49 40 3282-2685 rmueller@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com